CanDapi
Dry Powder Inhaler
Health Tech & Life Sciences
Non Active, Sep 2025 ceased to operate
Company Overview
Snapshot
Founded in March 2022 by Amnon Kritzman and Amnon Kritzman Kidron, CanDapi operates with 1–10 employees. The company has raised $3.5 million across one funding round from two investors. In July 2022, CanDapi secured funding from the Israel Innovation Authority.
Business overview
CanDapi is a Health Tech & Life Sciences company focused on drug delivery, specifically developing a breakthrough dry powder inhaler suitable for various generic and systemic medical powder drugs. The company's core product is designed to deliver medications and cannabinoids to the lungs, serving the pharmaceutical and medical cannabis industries with a B2B2C business model.
Log in to access full profile ›Company Intelligence Q&A
- When was CanDapi founded?
- CanDapi was founded in March 2022 by Amnon Kritzman and Amnon Kritzman Kidron.
- What is CanDapi's primary product?
- CanDapi's primary product is a dry powder inhaler designed for delivering medications and cannabinoids to the lungs, suitable for various medical powder drugs.
- What is CanDapi's current operational status?
- CanDapi is currently non-active, having ceased operations in September 2025.
- What is CanDapi's business model?
- CanDapi operates with a B2B2C business model, targeting the pharmaceutical and medical cannabis industries.
- What was a key early funding event for CanDapi?
- In July 2022, CanDapi secured funding from the Israel Innovation Authority as part of its Seed round.